Literature DB >> 28890258

Facile construction of bioreducible crosslinked polypeptide micelles for enhanced cancer combination therapy.

Hima Bindu Ruttala1, Natarajan Chitrapriya2, Kaliappan Kaliraj3, Thiruganesh Ramasamy1, Woo Hyun Shin1, Jee-Heon Jeong1, Jae Ryong Kim4, Sae Kwang Ku5, Han-Gon Choi6, Chul Soon Yong7, Jong Oh Kim8.   

Abstract

In this study, we developed pH and redox-responsive crosslinked polypeptide-based combination micelles for enhanced chemotherapeutic efficacy and minimized side effects. The stability and drug release properties of the polypeptide micelles were efficiency balanced by the corona-crosslinking of the triblock copolymer, poly(ethylene glycol)-b-poly(aspartic acid)-b-poly(tyrosine) (PEG-b-pAsp-b-pTyr) with coordinated redox and pH dual-sensitivity by introducing disulfide crosslinkages. Because of the crosslinking of the middle shell of the triblock polypeptide micelles, their robust structure was maintained in strong destabilization conditions and exhibited excellent stability. GSH concentrations were significantly higher in tumor tissue than in normal tissue, which formed the basis for our design. Drug release was elevated under redox and low acidic conditions. Furthermore, crosslinked micelles showed a superior anticancer effect compared to that of non-crosslinked micelles. Incorporation of docetaxel (DTX) and lonidamine (LND) in crosslinked polypeptide micelles increased the intracellular reactive oxygen species (ROS) level and oxidative stress and caused damage to intracellular components that resulted in greater apoptosis of cancer cells than when DTX or LND was used alone. The combination of DTX and LND in crosslinked micelles exhibited efficacious inhibition of tumor growth with an excellent safety profile compared to that reported for drug cocktail combinations and non-crosslinked micelles. Overall, redox/pH-responsive polypeptide micelles could be an interesting platform for efficient chemotherapy. STATEMENT OF SIGNIFICANCE: We have synthesized a biodegradable polypeptide block copolymer to construct a facile pH and redox-responsive polymeric micelle asan advanced therapeutic system for cancer therapy. We have designed a corona-crosslinked triblock copolymer (poly (ethylene glycol)-b-poly(aspartic acid)-b-poly(tyrosine) (PEG-b-pAsp-b-pTyr)) micelles co-loaded with docetaxel and lonidamine (cl-M/DL). The corona of triblock polymer was crosslinked to maintain its structural integrity in the physiological environment. The mitochondrial targeting LND is expected to generate ROS, oxidative stress and thereby synergize the chemotherapeutic efficacy of DTX in killing cancer cells. Consistently, cl-M/DL exhibited excellent antitumor efficacy in xenograft tumor model with remarkable tumor regression. Overall, we demonstrated the construction of bioreducible nanosystem for the effective synergistic delivery of DTX/LND in tumor tissues towards cancer treatment.
Copyright © 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Combination; Docetaxel; Lonidamine; Polypeptide polymers; Redox responsive

Mesh:

Substances:

Year:  2017        PMID: 28890258     DOI: 10.1016/j.actbio.2017.09.002

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  9 in total

Review 1.  Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment.

Authors:  Kasturee Chakraborty; Archana Tripathi; Sukumar Mishra; Argha Mario Mallick; Rituparna Sinha Roy
Journal:  Biosci Rep       Date:  2022-07-29       Impact factor: 3.976

2.  pH-triggered charge-reversal and redox-sensitive drug-release polymer micelles codeliver doxorubicin and triptolide for prostate tumor therapy.

Authors:  Chen Xu; Ri-Jin Song; Pei Lu; Jian-Chun Chen; Yong-Qiang Zhou; Gang Shen; Min-Jun Jiang; Wei Zhang
Journal:  Int J Nanomedicine       Date:  2018-11-08

3.  Enhanced antiproliferative effect of resveratrol in head and neck squamous cell carcinoma using GE11 peptide conjugated liposome.

Authors:  Tingting Zheng; Huanhuan Feng; Li Liu; Jiao Peng; Haitao Xiao; Tao Yu; Ziqian Zhou; Ying Li; Yuseng Zhang; Xiaohe Bai; Simeng Zhao; Yu Shi; Yun Chen
Journal:  Int J Mol Med       Date:  2019-02-13       Impact factor: 4.101

4.  A combinational chemo-immune therapy using an enzyme-sensitive nanoplatform for dual-drug delivery to specific sites by cascade targeting.

Authors:  Yanmei He; Lei Lei; Jun Cao; Xiaotong Yang; Shengsheng Cai; Fan Tong; Dennis Huang; Heng Mei; Kui Luo; Huile Gao; Bin He; Nicholas A Peppas
Journal:  Sci Adv       Date:  2021-02-05       Impact factor: 14.136

5.  Novel pH-sensitive and biodegradable micelles for the combined delivery of doxorubicin and conferone to induce apoptosis in MDA-MB-231 breast cancer cell line.

Authors:  Akram Rahmani; Hassan Zavvar Mousavi; Roya Salehi; Ahmad Bagheri
Journal:  RSC Adv       Date:  2020-08-07       Impact factor: 4.036

6.  Tumor-targeted dual-starvation therapy based on redox-responsive micelle nanosystem with co-loaded LND and BPTES.

Authors:  Zhenxiang Fu; Huiping Du; Siyu Meng; Mengjiao Yao; Pan Zhao; Xiang Li; Xinmin Zheng; Zhang Yuan; Hui Yang; Kaiyong Cai; Liangliang Dai
Journal:  Mater Today Bio       Date:  2022-10-03

Review 7.  Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer.

Authors:  Sangiliyandi Gurunathan; Min-Hee Kang; Muhammad Qasim; Jin-Hoi Kim
Journal:  Int J Mol Sci       Date:  2018-10-20       Impact factor: 5.923

8.  Co-delivery of sorafenib and crizotinib encapsulated with polymeric nanoparticles for the treatment of in vivo lung cancer animal model.

Authors:  Tian Zhong; Xingren Liu; Hongmin Li; Jing Zhang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

Review 9.  Nanoparticle-Mediated Photothermal Therapy Limitation in Clinical Applications Regarding Pain Management.

Authors:  Marzieh Salimi; Sara Mosca; Benjamin Gardner; Francesca Palombo; Pavel Matousek; Nicholas Stone
Journal:  Nanomaterials (Basel)       Date:  2022-03-10       Impact factor: 5.076

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.